Kwas Kargluminowy

Carglumic Acid, the active ingredient in Kwas Kargluminowy, is a carbamyl phosphate synthetase I activator presented as an oral formulation for oral use. It treats hyperammonemia caused by N‑acetylglutamate synthase deficiency and other urea cycle disorders, and improves metabolic stability through enhanced ammonia clearance. GNH USA supplies Kwas Kargluminowy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide and clinics, ensuring consistent quality and regulatory compliance across markets. Our distribution network includes transplant centres and specialty pharmacies, facilitating timely access to this essential therapy.

Carglumic Acid is used to manage hyperammonemia within the urea cycle disorder spectrum.

Hyperammonemia due to N‑acetylglutamate synthase deficiency: lowers plasma ammonia concentrations. Urea cycle disorders (e.g., carbamoyl phosphate synthetase I deficiency): supports the urea cycle to enhance ammonia detoxification. Hyperammonemia in organic acidemias: assists in reducing elevated ammonia levels.

Carglumic Acid may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Headache

Serious or Rare Side Effects: - Allergic reactions (including rash or anaphylaxis) - Metabolic acidosis - Hepatic dysfunction

When prescribing Carglumic Acid, consider the following precautions.

Renal function: assess baseline renal function and monitor during therapy. Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Pediatric patients: dose may require adjustment based on weight and metabolic status. Concomitant medications: review for potential interactions that may affect ammonia metabolism. Store at room temperature: keep in original container, protect from moisture and light.

Carglumic Acid can interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Sodium phenylbutyrate: may diminish the ammonia‑lowering effect of Carglumic Acid. - Carbamazepine: may increase risk of hepatic toxicity when combined.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may alter electrolyte balance, requiring monitoring. - Liver enzyme inducers (e.g., rifampicin): may reduce drug exposure. - Protein‑rich meals: may increase ammonia load, affecting efficacy.